Cargando…

Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2

As SARS-CoV-2 variants of concern (VOC) reduce the effectiveness of existing anti-COVID therapeutics, it is increasingly critical to identify highly potent neutralizing antibodies (nAbs) that bind to conserved regions across multiple variants, especially beta, delta, and omicron variants. Using sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bo, Xu, Hua, Liang, Zi-teng, Zhao, Tian-ning, Zhang, Xin, Peng, Tian-bo, Wang, You-chun, Su, Xiao-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747686/
https://www.ncbi.nlm.nih.gov/pubmed/36528147
http://dx.doi.org/10.1016/j.ijbiomac.2022.12.120
Descripción
Sumario:As SARS-CoV-2 variants of concern (VOC) reduce the effectiveness of existing anti-COVID therapeutics, it is increasingly critical to identify highly potent neutralizing antibodies (nAbs) that bind to conserved regions across multiple variants, especially beta, delta, and omicron variants. Using single-cell sequencing with biochemical methods and pseudo-typed virus neutralization experiments, here we report the characterization of a potent nAb BD-218, identified from an early screen of patients recovering from the original virus. We have determined the cryo-EM structure of the BD-218/spike protein complex to define its epitope in detail, which revealed that BD-218 interacts with a novel epitope on the receptor-binding domain (RBD) of the spike protein. We concluded that BD-218 is a highly effective and broadly active nAb against SARS-CoV-2 variants with promising potential for therapeutic development.